Adaptimmune Therapeutics Income Statement
Export
March 2023 - June 2021
Last Period Last
Next Period
Income (Quarterly)
Future Periods
2023-03 2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06
Actual Release Date 05/12/2023 -- 11/08/2022 08/04/2022 05/12/2023 -- 11/08/2022 08/04/2022
Operating Revenue Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Revenue 47.60M 11.03M 7.007M 5.538M 3.575M 1.417M 1.203M 3.095M
Cost of Goods Sold Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gross Profit -- -- -- -- -- -- -- --
Research and Development Expense 25.55M 23.05M 33.18M 34.74M 36.75M 29.50M 28.21M 28.87M
SG&A Expense 18.69M 12.92M 16.82M 16.89M 16.80M 15.48M 15.17M 14.99M
General and Administrative Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Sales and Marketing Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Rent and Landing Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income Statement Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Reconciled Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Amortization Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Amortization of Intangibles Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Provision for Doubtful Accounts Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Income and Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Comprehensive Income (Quarterly) Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Special Income and Charges Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Extraordinary Items, Income Statement Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Investment Write Off Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Interest Expense (Quarterly) Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Non-Operating Interest Income Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Pre-Tax Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Excise Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non Income Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Provision for Income Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income Attributable to Minority Interest Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Income 1.036M -29.25M -41.42M -44.52M -50.26M -38.86M -42.40M -39.07M
EPS Metrics (Quarterly)
Future Periods
2023-03 2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06
Actual Release Date 05/12/2023 -- 11/08/2022 08/04/2022 05/12/2023 -- 11/08/2022 08/04/2022
EPS Basic from Accounting Change Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Other Gains / Loss Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Tax Loss Carryforward Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Accounting Change Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Other Gain/Loss Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Tax Loss Carryforward Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted 0.0062 -0.18 -0.24 -0.30 -0.30 -0.24 -0.30 -0.24
Normalized Basic EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Diluted EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Dividends (Quarterly)
Future Periods
2023-03 2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06
Actual Release Date 05/12/2023 -- 11/08/2022 08/04/2022 05/12/2023 -- 11/08/2022 08/04/2022
Dividend Per Share Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Preferred Stock Dividend Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Shares (Quarterly)
Future Periods
2023-03 2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06
Actual Release Date 05/12/2023 -- 11/08/2022 08/04/2022 05/12/2023 -- 11/08/2022 08/04/2022
Average Basic Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Average Diluted Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links
2023-03 2022-12 2022-09 2022-06 2022-03 2021-12 2021-09 2021-06
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR
Restated -- -- -- -- Restated Restated Restated Restated